Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 5362506, 11 pages
http://dx.doi.org/10.1155/2016/5362506
Research Article

Renal Protection by Genetic Deletion of the Atypical Chemokine Receptor ACKR2 in Diabetic OVE Mice

1Department of Pediatrics, University of Louisville, Louisville, KY 40202, USA
2Department of Pathology, University of Louisville, Louisville, KY 40202, USA
3Department of Medicine, University of Louisville, Louisville, KY 40202, USA
4Department of Microbiology and Immunology, University of Louisville, Louisville, KY 40202, USA

Received 25 June 2015; Revised 25 September 2015; Accepted 27 September 2015

Academic Editor: Carlos Martinez Salgado

Copyright © 2016 Shirong Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Mora and J. F. Navarro, “Inflammation and diabetic nephropathy,” Current Diabetes Reports, vol. 6, no. 6, pp. 463–468, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. A. K. H. Lim and G. H. Tesch, “Inflammation in diabetic nephropathy,” Mediators of Inflammation, vol. 2012, Article ID 146154, 12 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. F. B. Hickey and F. Martin, “Diabetic kidney disease and immune modulation,” Current Opinion in Pharmacology, vol. 13, no. 4, pp. 602–612, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Wang, J. Chen, L. Chen, Y.-C. Tay, G. K. Rangan, and D. C. H. Harris, “Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein,” Journal of the American Society of Nephrology, vol. 8, no. 10, pp. 1537–1545, 1997. View at Google Scholar · View at Scopus
  5. C. Sassy-Prigent, D. Heudes, C. Mandet et al., “Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats,” Diabetes, vol. 49, no. 3, pp. 466–475, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. A. A. Eddy and C. M. Giachelli, “Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria,” Kidney International, vol. 47, no. 6, pp. 1546–1557, 1995. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Nguyen, F. Ping, W. Mu, P. Hill, R. C. Atkins, and S. J. Chadban, “Macrophage accumulation in human progressive diabetic nephropathy,” Nephrology, vol. 11, no. 3, pp. 226–231, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Y. Chow, D. J. Nikolic-Paterson, R. C. Atkins, and G. H. Tesch, “Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis,” Nephrology Dialysis Transplantation, vol. 19, no. 12, pp. 2987–2996, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. F. Navarro, F. J. Milena, C. Mora, C. León, and J. García, “Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration,” American Journal of Nephrology, vol. 26, no. 6, pp. 562–570, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. P. P. Wolkow, M. A. Niewczas, B. Perkins et al., “Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics,” Journal of the American Society of Nephrology, vol. 19, no. 4, pp. 789–797, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Rodríguez-Iturbe, Y. Quiroz, A. Shahkarami, Z. Li, and N. D. Vaziri, “Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat,” Kidney International, vol. 68, no. 3, pp. 1041–1047, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. Y.-G. Wu, H. Lin, X.-M. Qi et al., “Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes,” International Immunopharmacology, vol. 6, no. 3, pp. 445–453, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. G. Sayyed, M. Ryu, O. P. Kulkarni et al., “An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes,” Kidney International, vol. 80, no. 1, pp. 68–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Y. Nam, J. Paeng, S. H. Kim et al., “The MCP-1/CCR2 axis in podocytes is involved in apoptosis induced by diabetic conditions,” Apoptosis, vol. 17, no. 1, pp. 1–13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. R. J. B. Nibbs, S. M. Wylie, I. B. Pragnell, and G. J. Graham, “Cloning and characterization of a novel murine beta chemokine receptor, D6. Comparison to three other related macrophage inflammatory protein-1alpha receptors, CCR-1, CCR-3, and CCR-5,” The Journal of Biological Chemistry, vol. 272, no. 19, pp. 12495–12504, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Locati, Y. M. De La Torre, E. Galliera et al., “Silent chemoattractant receptors: D6 as a decoy and scavenger receptor for inflammatory CC chemokines,” Cytokine and Growth Factor Reviews, vol. 16, no. 6, pp. 679–686, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Jamieson, D. N. Cook, R. J. B. Nibbs et al., “The chemokine receptor D6 limits the inflammatory response in vivo,” Nature Immunology, vol. 6, no. 4, pp. 403–411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. M. de la Torre, C. Buracchi, E. M. Borroni et al., “Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 7, pp. 2319–2324, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. G. S. Whitehead, T. Wang, L. M. DeGraff et al., “The chemokine receptor D6 has opposing effects on allergic inflammation and airway reactivity,” American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 3, pp. 243–249, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M.-L. Berres, C. Trautwein, M. M. Zaldivar et al., “The chemokine scavenging receptor D6 limits acute toxic liver injury in vivo,” Biological Chemistry, vol. 390, no. 10, pp. 1039–1045, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Vetrano, E. M. Borroni, A. Sarukhan et al., “The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6,” Gut, vol. 59, no. 2, pp. 197–206, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Zheng, W. T. Noonan, N. S. Metreveli et al., “Development of late-stage diabetic nephropathy in OVE26 diabetic mice,” Diabetes, vol. 53, no. 12, pp. 3248–3257, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Zheng, Y. Huang, L. Yang, T. Chen, J. Xu, and P. N. Epstein, “Uninephrectomy of diabetic OVE26 mice greatly accelerates albuminuria, fibrosis, inflammatory cell infiltration and changes in gene expression,” Nephron. Experimental Nephrology, vol. 119, no. 1, pp. e21–e32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Yang, S. Brozovic, J. Xu et al., “Inflammatory gene expression in OVE26 diabetic kidney during the development of nephropathy,” Nephron: Experimental Nephrology, vol. 119, no. 1, pp. e8–e20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. S. Forbes, B. A. Thornhill, and R. L. Chevalier, “Proximal tubular injury and rapid formation of atubular glomeruli in mice with unilateral ureteral obstruction: a new look at an old model,” The American Journal of Physiology—Renal Physiology, vol. 301, no. 1, pp. F110–F117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Xu, Y. Huang, F. Li, S. Zheng, and P. N. Epstein, “FVB mouse genotype confers susceptibility to OVE26 diabetic albuminuria,” American Journal of Physiology—Renal Physiology, vol. 299, no. 3, pp. F487–F494, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Mezzano, C. Aros, A. Droguett et al., “NF-κB activation and overexpression of regulated genes in human diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 19, no. 10, pp. 2505–2512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Giunti, F. Barutta, P. C. Perin, and G. Gruden, “Targeting the MCP-1/CCR2 system in diabetic kidney disease,” Current Vascular Pharmacology, vol. 8, no. 6, pp. 849–860, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Bradford, H. Marshall, H. Robertson et al., “Cardiac allograft rejection: examination of the expression and function of the decoy chemokine receptor D6,” Transplantation, vol. 89, no. 11, pp. 1411–1416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Bazzan, M. Saetta, G. Turato et al., “Expression of the atypical chemokine receptor D6 in human alveolar macrophages in COPD,” Chest, vol. 143, no. 1, pp. 98–106, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. P. M. Garcia-Garcia, M. A. Getino-Melian, V. Dominguez-Pimentel, and J. F. Navarro-Gonzalez, “Inflammation in diabetic kidney disease,” World Journal of Diabetes, vol. 5, no. 4, pp. 431–443, 2014. View at Publisher · View at Google Scholar
  32. F. Chow, E. Ozols, D. J. Nikolic-Paterson, R. C. Atkins, and G. H. Tesch, “Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury,” Kidney International, vol. 65, no. 1, pp. 116–128, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. M. D. Singh, V. King, H. Baldwin et al., “Elevated expression of the chemokine-scavenging receptor D6 is associated with impaired lesion development in psoriasis,” American Journal of Pathology, vol. 181, no. 4, pp. 1158–1164, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. X.-H. Zeng, Z.-L. Ou, K.-D. Yu et al., “Coexpression of atypical chemokine binders (ACBs) in breast cancer predicts better outcomes,” Breast Cancer Research and Treatment, vol. 125, no. 3, pp. 715–727, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. G.-J. Lin, S.-H. Huang, Y.-W. Chen et al., “Transgenic expression of murine chemokine decoy receptor D6 by islets reveals the role of inflammatory CC chemokines in the development of autoimmune diabetes in NOD mice,” Diabetologia, vol. 54, no. 7, pp. 1777–1787, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Liu, G. J. Graham, A. Damodamn et al., “Cutting edge: the silent chemokine receptor D6 is required for generating T cell responses that mediate experimental autoimmune encephalomyelitis,” The Journal of Immunology, vol. 177, no. 1, pp. 17–21, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Bordon, C. A. H. Hansell, D. P. Sester, M. Clarke, A. M. Mowat, and R. J. B. Nibbs, “The atypical chemokine receptor D6 contributes to the development of experimental colitis,” Journal of Immunology, vol. 182, no. 8, pp. 5032–5040, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. A. R. Hajrasouliha, Z. Sadrai, H. K. Lee, S. K. Chauhan, and R. Dana, “Expression of the chemokine decoy receptor D6 mediates dendritic cell function and promotes corneal allograft rejection,” Molecular Vision, vol. 19, pp. 2517–2525, 2013. View at Google Scholar · View at Scopus
  39. B. Savino, M. G. Castor, N. Caronni et al., “Control of murine Ly6Chigh monocyte traffic and immunosuppressive activities by atypical chemokine receptor D6,” Blood, vol. 119, no. 22, pp. 5250–5260, 2012. View at Publisher · View at Google Scholar · View at Scopus